# NSPR earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/NSPR) · [Earnings tab](https://www.lopjlb.com/stock/NSPR?tab=earnings)

Updated: 2026-08-17T04:14:58

Quarters analyzed: 8

## Cross-quarter narrative

In mid‑2024 InspireMD was still building a commercial foundation while pursuing a H1‑2025 PMA for CGuard Prime, reporting modest revenue growth and a cash boost from a $17.9M milestone. By Q3‑2024 the PMA was filed and the company added a Miami headquarters, but gross margins fell as operating spend rose. The Q4‑2024 update confirmed the PMA remained on track, added a US launch plan and highlighted mounting margin pressure and execution risk. Early 2025 introduced regulatory delay signals – a site‑audit postponement pushed the FDA decision to Q3‑2025 and marked the PMA as at‑risk, while cash fell to $26 M despite continued hiring. After FDA clearance in Q2‑2025 the US rollout began, supported by a $58 M raise, yet gross margins compressed further and the TCAR pivotal study slipped to 2027. Q3‑2025 showed the first post‑approval quarter with strong US case volume, margin expansion and a cash pile of $63.4 M. The Q4‑2025 and Q1‑2026 periods revealed a voluntary pause on the CGuard Prime 135 delivery system, re‑introducing regulatory uncertainty and a withdrawn guidance, while international demand stayed robust. Across the series, the firm moved from pre‑approval buildup to commercial launch, but repeatedly faced regulatory timing risk, commercial execution challenges, and margin volatility despite periodic financing infusions.

## Latest CallCard · Q1

InspireMD Q1 revenue $3.4M (+122% YoY) but voluntarily paused US CGuard Prime 135 delivery system; withdrew 2026 guidance; targets original CGuard FDA approval Q3 2026 to reenter US market.

**Guidance:** withdrawn — Full-year 2026 revenue guidance withdrawn due to US commercial pause; will reassess after anticipated FDA approval of original CGuard delivery system in Q3 2026.

**Tone:** mgmt 0.2 · Q&A pressure 0.5 · divergence 0.3

Management acknowledges setback but frames pause as proactive, emphasizes clear path forward, strong international growth, and confidence in long-term trajectory.

### Demand visibility

Strong international demand (48% YoY growth); US demand evidenced by controlled launch growth but currently paused.

International revenue $2.2M (+48% YoY) driven by unit volume; US revenue $1.2M (+36% sequential) from controlled CGuard Prime launch before pause. Physician receptivity described as strong for both original CGuard and Prime platforms. VAC processes underway at accounts for rapid relaunch upon FDA approval.

### Margins / costs

GAAP gross margin 20.2% (non-GAAP 34.1% ex-impairment); impairment charge $473K for excess inventory; OpEx rising on R&D for C-GUARDIANS III trial.

Gross profit $0.7M (20.2%) vs $0.3M (19.1%) prior year; mix shift to higher-margin US sales offset by $473K inventory impairment. Non-GAAP adjusted gross margin 34.1% below expectations due to Tel Aviv operations compensation during conflict. Total OpEx $14.7M (+$2.9M YoY) from US commercial launch staffing/marketing. Expect OpEx to increase slightly with R&D investment for C-GUARDIANS III; commercial headcount paused pending FDA timeline clarity.

### Capital allocation

Cash $41.6M; investing in R&D for clinical trial; pausing commercial headcount; funding Prime 135 redesign and regulatory submissions.

Cash and marketable securities $41.6M at March 31, 2026 vs $54.2M at end of 2025. Q2 2026 to absorb ~$1.35M in recall reserves ($700K returns + $650K inventory/remediation). Capital directed to C-GUARDIANS III trial initiation, Prime 135 V&V testing, and regulatory submissions for original CGuard and Prime 80 TCAR. Commercial hiring paused until FDA approval visibility improves.

### Milestones

- **CGuard Prime 135 delivery system redesign** [at_risk]: Voluntary US commercialization pause; root cause identified, design changes made, V&V testing underway; target resubmission and approval early 2027 or sooner.
- **Original CGuard 135 delivery system FDA approval** [on_track]: Anticipated FDA approval Q3 2026 (August window); used in >70,000 cases globally and majority of C-GUARDIANS PMA trial; manufacturing capacity ready.
- **CGuard Prime 80 for TCAR indication FDA approval** [on_track]: Expected approval H2 2026; would double US addressable market; short shaft indicated for TCAR procedures.
- **C-GUARDIANS III clinical trial initiation** [new]: FDA approved initiation; evaluates next-generation SwitchGuard neuroprotection system with CGuard Prime 80 for TCAR; enrollment starting soon.
- **SwitchGuard neuroprotection system for TCAR** [new]: Next-generation neuroprotection system; part of C-GUARDIANS III trial; would complete full TCAR toolkit upon approval.
- **International commercial expansion** [on_track]: 48% YoY revenue growth in Q1 2026; standardized on original CGuard delivery system; demand growing across mature markets.
- **US relaunch with original CGuard system** [on_track]: VAC processes initiated at accounts; team preparing for rapid relaunch upon FDA approval; physician receptivity described as strong.
- **CGuard Prime 135 improved platform resubmission** [at_risk]: Design changes completed; V&V testing in progress; regulatory pathway (statutory vs expedited) undetermined; targeting early 2027 approval.

### Fears / risks

- **FDA approval timeline uncertainty**: Original CGuard approval target Q3 2026 and Prime 135 redesign target early 2027 both uncertain; design change classification (statutory vs expedited) unresolved.
- **US revenue gap during pause**: No US commercial activity expected until original CGuard approval; international revenue only source during interim period.
- **Competitive risk during US absence**: Competitors may gain share while InspireMD absent from US market; physician access loss could erode momentum.
- **Recall and impairment costs**: Q2 2026 to absorb ~$700K customer returns reserve and ~$650K inventory impairment/remediation reserve.
- **OpEx increasing amid revenue uncertainty**: R&D spending rising for C-GUARDIANS III trial while US revenue paused; commercial headcount paused but fixed costs remain.
- **Physician adoption risk**: Delivery system issues could undermine physician confidence despite strong stent clinical data; some centers experienced deployment challenges.
- **International market perception**: Risk that US voluntary action creates negative perception in OUS markets, though management reports no slowdown expected.
- **Regulatory pathway ambiguity for Prime 135 redesign**: Whether redesign qualifies for expedited review or statutory timeline remains undetermined, affecting return-to-market timing.

### Key quotes

> “this action is not related to the safety or performance of the CGuard stent implant, which continues to demonstrate best-in-class clinical outcomes”

> “we anticipate FDA approval in the third quarter of 2026, which would enable us to reenter the U.S. market with a proven and highly reliable platform”

> “we withdrew our prior full year 2026 revenue guidance, at least until the expected FDA approval of our original CGuard stent delivery system, which we believe will take place in the third quarter of 2026”

> “we have a very clear understanding of what needs to be done. We're confident we can expedite that quickly and get that into the FDA so that we can get things back on track”

> “many of them don't want to lose access today, and all of them are looking forward to gaining access as soon as it's available”

## Quarter one-liners

- **2026 Q1:** InspireMD Q1 revenue $3.4M (+122% YoY) but voluntarily paused US CGuard Prime 135 delivery system; withdrew 2026 guidance; targets original CGuard FDA approval Q3 2026 to reenter US market.
- **2025 Q4:** InspireMD Q4 revenue up 62% YoY to $3.1M on US CGuard Prime launch; FY26 guidance $13-15M (45-65% growth) with TCAR indication and enhanced delivery system in H2.
- **2025 Q3:** InspireMD posts 39% YoY revenue growth to $2.5M in first full quarter post-FDA approval, with >100 US cases, $63.4M cash after $58M financing, and Q4 guidance of $2.5-3.0M.
- **2025 Q2:** InspireMD launched US commercial rollout of FDA-approved CGuard Prime carotid stent, raised $58M, but Q2 revenue flat at $1.8M with widening losses as OpEx surges 55% for launch build-out; TCAR pivotal study delayed to 2027.
- **2025 Q1:** InspireMD Q1 revenue $1.53M flat YoY; CGuard Prime FDA approval targeted Q3 2025 after site audit delay; US commercial buildout underway with ~20 hires; C-GUARDIANS II enrollment strong for H1 2026 approval; cash $26M.
- **2024 Q4:** InspireMD reported Q4 revenue of $1.95M (10.6% YoY) and full-year $7M (13% YoY), remains on track for H1 2025 FDA approval of CGuard Prime, building US commercial team (13 hires), advancing CGUARDIANS II/III trials, targeting SwitchGuard approval H2 2026; no revenue guidance given, OpEx rising sharp
- **2024 Q3:** InspireMD Q3 revenue $1.81M (+16%), 3,129 CGuard implants sold; PMA submitted for CGuard Prime, FDA decision early 2025; U.S. launch prep with Miami HQ, commercial hiring; CGuardians II IDE approved for TCAR, SwitchGuard in development.
- **2024 Q2:** InspireMD reports Q2 revenue of $1.74M (+5.4%), advances CGuard PMA submission targeting H1 2025 U.S. approval, builds commercial team, and secures $17.9M milestone financing.

## Theme arcs

- **Regulatory approval risk** (deteriorating): Initial on‑track PMA became at‑risk in Q1‑2025 and resurfaced with new redesign delays in Q1‑2026
- **US commercial execution** (improving): Build‑out progressed to launch in Q2‑2025, delivered in Q3‑2025, then paused in Q1‑2026
- **Revenue trajectory** (improving): From $1.74 M in Q2‑2024 to $3.4 M in Q1‑2026, driven by US launch
- **Margin pressure** (deteriorating): Gross margin fell to 17.6% in Q2‑2025 before expanding to 34.2% in Q3‑2025, then back to ~20% in Q1‑2026
- **Cash position & financing** (stable): Cash declined from $47.2 M to $26 M, then bolstered to $63.4 M after $58 M raise
- **Clinical trial progress** (stable): CGuardians II remains on‑track; CGuardians III IDE delayed in Q2‑2025, later back on track
- **Competitive landscape** (new): Emerging risk noted in Q1‑2026 as US market pause could cede share

## Fear persistence

- **Regulatory timing** [recurring]: Audit delay Q1‑2025 and redesign risk Q1‑2026 keep approval uncertainty alive
- **Commercial execution** [recurring]: Build‑out, launch pacing, and pause of Prime 135 create ongoing execution risk
- **Margin compression** [recurring]: Higher COGS and compensation pressure margins fluctuated across periods
- **Cash burn** [recurring]: Operating expense surge reduced cash, offset by periodic financing
- **Competitive risk** [new]: Q1‑2026 pause raises concern of rivals gaining US share

## Guidance path

2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:withdrawn

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/NSPR`